On August 11, 2026, NCPA released the results of one of the most compelling real-world pharmacy clinical outcome studies in years. The numbers are extraordinary enough that every pharmacist should know them by heart. More importantly, the model is replicable anywhere in the country.
What the Program Actually Did
A collaboration between NCPA’s Innovation Center, CPESN Community Health, and Bristol Myers Squibb deployed a cardiovascular risk screening and care coordination program across 25 independent community pharmacies in six states: Alabama, Arkansas, Kentucky, Louisiana, Mississippi, and Missouri. These states sit in what epidemiologists call the Stroke Belt, a region characterized by disproportionately high rates of cardiovascular disease, stroke mortality, and hypertension, with limited access to primary care providers in most rural counties.
The 25 participating pharmacies logged 11,188 encounters for 9,820 patients across 694 different ZIP codes, delivering more than 20,000 discrete interventions in just six months. The program may have saved hundreds of lives, improved outcomes for thousands of patients, and saved millions of dollars by preventing hospitalization.
The specific clinical services embedded into pharmacy workflow included cardiovascular risk screening, atrial fibrillation detection, blood pressure monitoring, and longitudinal care coordination. Patients who previously had no regular contact with the healthcare system were being identified, screened, and referred for the first time through a touchpoint they already used regularly: their local pharmacy.
The Voice from the Ground That Explains Why This Works
NCPA CEO B. Douglas Hoey described the geographic reality that makes pharmacist-led cardiovascular screening uniquely powerful in this region: “In this part of the country, like most of rural America, independent community pharmacies are often the only accessible healthcare providers. Many people in these areas may not have ready access to a doctor, but they frequently visit their local pharmacy. So, the local pharmacist is in a good position to identify at-risk patients, provide screening and counseling, connect patients with social services, and refer them to physicians for medical care.”
One of the participating pharmacists put the access logic in sharper terms: “Community pharmacists practicing in underserved areas understand, perhaps better than most, that healthcare needs to move into neighborhoods and living rooms to be effective. We must reach people where they live. Training our staff as community health workers only amplifies the impact community pharmacies have on health-related social needs on a daily basis.”
The community health worker element is worth noting specifically. The program trained pharmacy staff, not just the pharmacist, as CHWs. That staffing model extends the clinical reach of the pharmacist’s screening program without requiring the pharmacist to be physically present for every initial encounter, which is what makes 11,188 encounters in six months across 25 pharmacies operationally believable.
Why the Stroke Belt Geography Is the Right Place to Prove This
The six states in this pilot are not randomly selected. They represent the geography where pharmacist-led cardiovascular screening has the highest possible clinical impact, and where the failure of traditional healthcare delivery is most documentable.
The Stroke Belt, referring to a cluster of southeastern U.S. states with stroke mortality rates significantly above the national average, has been documented in epidemiological literature since the 1960s. Stroke mortality in the Stroke Belt states runs 10% to 40% higher than in the rest of the United States. Hypertension prevalence exceeds national averages. Atrial fibrillation rates track with the same demographic and metabolic risk factor patterns that characterize Stroke Belt populations: older adults, higher rates of obesity and diabetes, lower rates of regular primary care access.
The physician-to-patient ratio in rural counties across these six states tells the access story without editorializing. Many rural counties in Mississippi, Alabama, and Arkansas have no primary care physician practicing within the county. The pharmacist is not competing with primary care in these markets. The pharmacist is the primary care contact for a patient population that has no other regular healthcare touchpoint.
In that context, 9,820 patients accessing cardiovascular screening through 25 pharmacies is not a pilot. It is proof that the pharmacy is the actual primary care access point for this population.
The Clinical Logic Behind Each Intervention Component
The program focused on four specific clinical service components, each of which targets a different point in the cardiovascular risk chain.
Blood pressure monitoring. Hypertension affects approximately 47% of U.S. adults and is the leading modifiable risk factor for stroke and cardiovascular disease. It is also largely asymptomatic until it produces a catastrophic event. The patient who visits their pharmacy every month to pick up a maintenance medication and has never had their blood pressure checked in that setting represents a systematic identification failure that this program corrected. Blood pressure screening requires 90 seconds, a validated device, and documentation.
Atrial fibrillation detection. AF is the most common cardiac arrhythmia, affecting approximately 6 million Americans, and is responsible for approximately 15% to 20% of all strokes. AF is often asymptomatic between episodes and easily missed without systematic rhythm screening. A pharmacist using a validated pulse assessment protocol or a point-of-care ECG device such as AliveCor’s KardiaMobile can identify AF in the same brief encounter where they provide a refill counseling interaction. In rural populations with limited cardiology access, the pharmacist who catches AF and initiates the anticoagulation referral conversation may be preventing a stroke that would otherwise have been the first clinical signal of the disease.
Cardiovascular risk screening. The ASCVD risk calculator, using age, sex, blood pressure, cholesterol values, smoking status, and diabetes status, generates a 10-year cardiovascular event risk score that directly guides statin initiation and aspirin use discussions. For patients whose most recent labs are in your pharmacy dispensing system, this calculation takes two minutes and produces an actionable clinical recommendation. The patient at high cardiovascular risk who has never received this calculation has not had this risk quantified for them by anyone.
Longitudinal care coordination. The program’s structure included not just the screening encounter but the follow-up referral tracking and social needs assessment that determine whether the screening translates into actual clinical change. The community health worker training embedded in the program specifically built CHW skills for identifying social determinants, including food insecurity, transportation barriers, and medication cost challenges, that directly affect a patient’s ability to act on cardiovascular risk reduction recommendations.
The Financial Case Hiding Inside the Clinical Story
This newsletter has covered the risk management identity framework and the evidence currency principles across several recent issues. The NCPA Stroke Belt program is the clearest single dataset in pharmacy’s 2026 record for making both arguments.
A single prevented stroke hospitalization averages $20,000 to $40,000 in direct hospital costs, plus rehabilitation, long-term care, lost productivity, and caregiver costs that push the total economic burden of a single stroke event to $73,000 in lifetime costs on average. A single prevented cardiovascular hospitalization for acute MI or heart failure exacerbation averages $18,000 to $30,000 in direct costs.
The NCPA program delivered 11,188 encounters and 20,000-plus interventions across 9,820 patients. If even 2% of those patients avoided a single cardiovascular hospitalization because of being identified, screened, referred, and connected to care through their local pharmacy, the prevented hospitalization count exceeds 190 events. At a conservative average direct hospitalization cost of $20,000, that is $3.8 million in avoided healthcare costs from 25 pharmacies over six months.
The six-month operating cost of a pharmacy-based cardiovascular screening program at the scale NCPA deployed, including staff training, device costs, and documentation infrastructure, runs well under $50,000 per pharmacy at most. The return on that investment is not theoretical. The NCPA data provides the numerator.
This Is the Proof of Concept the Advocacy Movement Needed
This newsletter has tracked the Main Street Pharmacy Access Act, the CMS ACCESS Model, the ADA 2026 Standards’ explicit naming of pharmacists in cardiorenal coordination, the JAMA study doubling SGLT2 inhibitor initiation rates through pharmacist outreach, the Geisinger RPM program achieving 74% blood pressure control, and the PLOS ONE Shields-UMass diabetes coaching study generating 22 fewer hospital admissions per 100 patients.
The NCPA Stroke Belt program adds something specific to that evidence set that the others don’t: it proves the model works in exactly the communities that the pharmacy access and equity arguments have always been about. Not a health system with sophisticated informatics infrastructure. Not an urban academic medical center with a clinical pharmacy residency program. Twenty-five independent community pharmacies in rural Alabama, Arkansas, Kentucky, Louisiana, Mississippi, and Missouri, in the exact geography where cardiovascular disease kills the most people and where the healthcare system has historically reached them least.
That is the proof-of-concept the pharmacy advocacy movement has been building toward. Not a theoretical argument about pharmacist capability. Not a position paper. A real-world dataset from 25 actual pharmacies in the hardest-to-reach communities in the country, showing that pharmacists are finding, screening, and referring the patients at highest risk of stroke and heart disease, at a cost that is a fraction of a single prevented hospitalization.
When a pharmacist walks into a conversation with an ACCESS-participating ACO, a Medicaid managed care plan serving rural beneficiaries, a rural health clinic looking for a community health partner, or a state health department managing Stroke Belt population health programs, this dataset is the receipt.
Your Five Patient Audit Starting Today
The NCPA program’s structure is replicable without a national collaboration, a six-state pilot, or pharmaceutical industry funding. It requires a pharmacist who decides to screen systematically rather than waiting for patients to present with a cardiovascular complaint.
Identify five patients in your practice right now who you suspect have uncontrolled cardiovascular risk factors but who have not seen a physician in the past 12 months. The profile to look for: a patient on an antihypertensive who refills inconsistently, suggesting adherence or access challenges. A patient on metformin or an SGLT2 inhibitor for diabetes who has no cardiology medication on profile. A patient over 60 with no documented cardiovascular risk assessment in your dispensing history. A patient whose blood pressure you have never taken despite filling their lisinopril for two years.
For each of those five patients, run a 90-second screening at their next pickup: blood pressure measurement, pulse regularity assessment for AF, documentation of smoking status and diabetes diagnosis if relevant, and a brief ASCVD risk conversation if labs are available in your system.
For any patient whose blood pressure exceeds 140/90 or whose pulse is irregular, document the finding and initiate the prescriber referral conversation before they leave the counter.
That five-patient audit is the beginning of your cardiovascular screening program. The NCPA program ran 11,188 encounters from exactly this kind of systematic, pharmacist-led approach. The infrastructure is the same: a pharmacist, a blood pressure cuff, a pulse check, and the decision to make screening part of every chronic disease patient interaction rather than an occasional exception.
Sources: NCPA Press Release (Rural Pharmacies Identify Thousands of Patients at Risk for Stroke and Heart Disease, Save Lives, and Cut Costs, August 11, 2026), Drug Topics (How Rural Pharmacies Are Screening Thousands and Cutting Costs, August 11, 2026), NCPA Innovation Center (Stroke Belt Pilot Program Overview and Six-Month Results), CPESN Community Health (Community Health Worker Training Model for Independent Pharmacy), American Heart Association (Stroke Belt Geography and Cardiovascular Mortality Data), CDC (Atrial Fibrillation Facts and Statistics), AHA/ACC ASCVD Risk Calculator and Guidelines, AHRQ (Average Cost of Stroke Hospitalization and Lifetime Economic Burden)